Μετάβαση στο περιεχόμενο

Top News from the IASLC 19th World Conference on Lung Cancer 2018

IASLC_1200_x_628

Roche’s investigational medicine entrectinib showed a durable response of more than two years in people with a specific type of lung cancer

September 24, 2018

Roche has announced results for its investigational medicine entrectinib, from an integrated analysis of the pivotal phase II STARTRK-2, phase I STARTRK-1 and phase I ALKA trials, which showed that entrectinib shrank tumours (objective response rate; ORR) in 77.4% of people with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). In addition, entrectinib demonstrated a durable response of more than two years (duration of response [DoR] = 24.6 months). Importantly, entrectinib was shown to shrink tumours in more than half of people with cancer in the central nervous system (CNS) (intracranial ORR: 55.0%). The safety profile of entrectinib was consistent with that seen in previous analyses, and no new safety signals were identified. Based on the integrated analysis of these studies, Roche plans to submit these data to global health authorities.

Oncimmune Demonstrates Clinical Utility of Early Lung Cancer Detection TestEarlyCDT®

September 25, 2018

Oncimmune Holdings plc, a leading early cancer detection company developing and commercializing its proprietary EarlyCDT® liquid biopsy platform technology, has presented new data demonstrating the clinical utility of EarlyCDT-Lung, a simple blood test for the early detection of lung cancer, in determining malignancy risk in indeterminate pulmonary nodules (IPNs). In a presentation at the IASLC 19th World Conference on Lung Cancer in Toronto, Canada, Oncimmune researchers reported that for IPNs of 6-20mm with a lung cancer probability of >30%, combining a positive EarlyCDT-Lung result with a standard risk calculator produced a positive predictive value (PPV) of 91%, versus a 48% PPV using the standard risk calculator alone. Additionally, use of EarlyCDT-Lung led to a resection rate for benign disease of only 9%, compared with the average of 20-25% reported in previously published lung cancer screening trials.

Imfinzi is the first immunotherapy to demonstrate significant overall survival benefit in unresectable, Stage III lung cancer

September 25, 2018

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi during the Presidential Symposium of the IASLC 19th World Conference on Lung Cancer. Results from the Phase III PACIFIC trial were published simultaneously in the New England Journal of Medicine, showing Imfinzi (durvalumab) significantly improved OS, the second primary endpoint of the trial, compared to standard of care regardless of PD-L1 expression, reducing the risk of death by 32% (HR 0.68, 99.73% CI 0.47-0.997; p=0.0025).

Takeda Presented Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial Showing a Reduction in Risk of Disease Progression or Death of More Than 50 Percent Versus Crizotinib in First-Line Advanced ALK+ NSCLC

September 25, 2018

Takeda Pharmaceutical Company Limited has announced results from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial, demonstrating that ALUNBRIG reduced the risk of disease progression or death, known as progression-free survival (PFS), as assessed by a blinded independent review committee (BIRC), by more than fifty percent compared to crizotinib in adults with anaplastic lymphoma kinase-positive (ALK+) locally advanced or metastatic non-small cell lung cancer (NSCLC) who had not received a prior ALK inhibitor. Findings from the first interim analysis of the ALTA-1L trial were presented during the Presidential Symposium at IASLC 2018. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC.

Mersana Therapeutics Presented New Preclinical Data on XMT-1536 

September 25, 2018

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin® and other proprietary platforms, has announced preclinical data involving the company’s clinical candidate, XMT-1536, a NaPi2b-targeting ADC.

Roche’s Tecentriq in combination with chemotherapy helped people live significantly longer as an initial treatment for people with extensive-stage small cell lung cancer

September 25, 2018

Roche has announced positive results from the Phase III IMpower133 study of Tecentriq® (atezolizumab) plus carboplatin and etoposide (chemotherapy) for the initial (first-line) treatment of people with previously-untreated extensive-stage small cell lung cancer (ES-SCLC). The analysis showed that Tecentriq and chemotherapy helped people live significantly longer compared with chemotherapy alone (overall survival [OS]=12.3 versus 10.3 months; hazard ratio [HR]=0.70, 95% CI: 0.54-0.91; p=0.0069) in the intention-to-treat (ITT) population.1 The Tecentriq -based combination also significantly reduced the risk of disease worsening or death (progression-free survival, PFS) compared with chemotherapy alone (PFS=5.2 versus 4.3 months; HR=0.77, 95% CI: 0.62-0.96; p=0.017). Safety for the Tecentriq and chemotherapy combination appeared consistent with the known safety profile of the individual medicines, and no new safety signals were identified with the combination.

Loxo Oncology Announces LOXO-292 Durability Update in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer from LIBRETTO-001 

Sept. 25, 2018

Loxo Oncology, Inc., a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, has announced updated interim clinical data for LOXO-292 from the global Phase 1/2 LIBRETTO-001 trial in patients with RET fusion-positive non-small cell lung cancer (NSCLC). In these 38 patients, approximately 3.5 months of additional patient follow-up were available, as were first follow-up scans for the eight patients most recently enrolled. Twenty-five of 26 (96%) responding patients remained on therapy, with median follow-up of 9.5 months. Inclusion of new restaging data for the most recently enrolled patients resulted in a 68% confirmed overall response rate in the presented subset.

HER2 Mutated or HER2 Expressing Non-Small Cell Lung Cancer 

September 24, 2018

Daiichi Sankyo Company, Limited announced that updated phase 1 safety and efficacy data for [fam-] trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody drug conjugate (ADC), were presented for a subgroup of patients with heavily pretreated HER2 mutated or HER2 expressing non-small cell lung cancer (NSCLC) during an Oral Session at the IASLC 19th World Conference on Lung Cancer #WCLC2018

 

Πηγή

Thanasis Chalikias Προβολή όλων

A Product Manager with expertise in pharma marketing and sales operations

Σχολιάστε

Συνδεθείτε για να δημοσιεύσετε το σχόλιο σας:

Λογότυπο WordPress.com

Σχολιάζετε χρησιμοποιώντας τον λογαριασμό WordPress.com. Αποσύνδεση /  Αλλαγή )

Φωτογραφία Google+

Σχολιάζετε χρησιμοποιώντας τον λογαριασμό Google+. Αποσύνδεση /  Αλλαγή )

Φωτογραφία Twitter

Σχολιάζετε χρησιμοποιώντας τον λογαριασμό Twitter. Αποσύνδεση /  Αλλαγή )

Φωτογραφία Facebook

Σχολιάζετε χρησιμοποιώντας τον λογαριασμό Facebook. Αποσύνδεση /  Αλλαγή )

Σύνδεση με %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Αρέσει σε %d bloggers: